Which has stronger earnings and valuation, AORT or ITGR?

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.50 $9.77M -$0.07 N/A Integer $1.85B 2.32 $102.81M $3.66 34.60

Is AORT or ITGR more profitable?

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% Integer 6.97% 12.79% 6.48%

Does the media favor AORT or ITGR?

In the previous week, Integer had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for Integer and 1 mentions for Artivion. Integer's average media sentiment score of 0.40 beat Artivion's score of 0.00 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LIVN or AORT?

Artivion has lower revenue, but higher earnings than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.03 -$242.47M $3.38 22.61 Artivion $441.33M 2.50 $9.77M -$0.07 N/A

Is LIVN or AORT more profitable?

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Artivion -0.67% 6.07% 2.93%

Does the media refer more to LIVN or AORT?

In the previous week, LivaNova had 1 more articles in the media than Artivion. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Artivion. LivaNova's average media sentiment score of 0.34 beat Artivion's score of 0.00 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, AORT or PLSE?

Artivion has higher revenue and earnings than Pulse Biosciences. Artivion is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.50 $9.77M -$0.07 N/A Pulse Biosciences $350K 10,215.43 -$72.78M -$1.18 N/A

Does the media favor AORT or PLSE?

In the previous week, Pulse Biosciences had 2 more articles in the media than Artivion. MarketBeat recorded 3 mentions for Pulse Biosciences and 1 mentions for Artivion. Pulse Biosciences' average media sentiment score of 0.61 beat Artivion's score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRTC or AORT?

In the previous week, iRhythm Technologies had 9 more articles in the media than Artivion. MarketBeat recorded 10 mentions for iRhythm Technologies and 1 mentions for Artivion. iRhythm Technologies' average media sentiment score of 0.20 beat Artivion's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AORT or ATRC?

Artivion has higher earnings, but lower revenue than AtriCure. Artivion is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.50 $9.77M -$0.07 N/A AtriCure $534.53M 5.36 -$11.45M $0.21 268.43

Is AORT or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Artivion's net margin of -0.67%. Artivion's return on equity of 6.07% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% AtriCure 1.85% 2.34% 1.77%

Does the media favor AORT or ATRC?

In the previous week, AtriCure had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for AtriCure and 1 mentions for Artivion. AtriCure's average media sentiment score of 0.22 beat Artivion's score of 0.00 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Artivion (AORT) Competitors

$22.61 +0.30 (+1.33%)

Closing price 10/5/2026 03:59 PM Eastern

Extended Trading

$22.85 +0.24 (+1.06%)

As of 09:19 AM Eastern

Compare

AORT vs. ITGR, LIVN, PLSE, IRTC, and ATRC

Should you buy Artivion stock or one of its competitors? Artivion's main competitors and comparable companies include Integer (ITGR), LivaNova (LIVN), Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Artivion compare to Integer?

Artivion (NYSE:AORT) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Integer has a net margin of 6.97% compared to Artivion's net margin of -0.67%. Integer's return on equity of 12.79% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Integer	6.97%	12.79%	6.48%

Artivion currently has a consensus target price of $44.83, indicating a potential upside of 98.32%. Integer has a consensus target price of $109.86, indicating a potential downside of 13.24%. Given Artivion's stronger consensus rating and higher possible upside, analysts plainly believe Artivion is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 6.3% of Artivion shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Artivion has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Integer has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Integer has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.50	$9.77M	-$0.07	N/A
Integer	$1.85B	2.32	$102.81M	$3.66	34.60

In the previous week, Integer had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for Integer and 1 mentions for Artivion. Integer's average media sentiment score of 0.40 beat Artivion's score of 0.00 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Integer beats Artivion on 10 of the 16 factors compared between the two stocks.

How does Artivion compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Artivion (NYSE:AORT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artivion has lower revenue, but higher earnings than LivaNova. Artivion is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.03	-$242.47M	$3.38	22.61
Artivion	$441.33M	2.50	$9.77M	-$0.07	N/A

In the previous week, LivaNova had 1 more articles in the media than Artivion. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for Artivion. LivaNova's average media sentiment score of 0.34 beat Artivion's score of 0.00 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Artivion has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

LivaNova currently has a consensus price target of $84.13, suggesting a potential upside of 10.07%. Artivion has a consensus price target of $44.83, suggesting a potential upside of 98.32%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

LivaNova has a net margin of 12.82% compared to Artivion's net margin of -0.67%. LivaNova's return on equity of 16.35% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Artivion	-0.67%	6.07%	2.93%

Summary

LivaNova beats Artivion on 10 of the 15 factors compared between the two stocks.

How does Artivion compare to Pulse Biosciences?

Artivion (NYSE:AORT) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

86.4% of Artivion shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artivion currently has a consensus price target of $44.83, suggesting a potential upside of 98.32%. Pulse Biosciences has a consensus price target of $50.20, suggesting a potential downside of 0.59%. Given Artivion's higher possible upside, analysts clearly believe Artivion is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Artivion has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

In the previous week, Pulse Biosciences had 2 more articles in the media than Artivion. MarketBeat recorded 3 mentions for Pulse Biosciences and 1 mentions for Artivion. Pulse Biosciences' average media sentiment score of 0.61 beat Artivion's score of 0.00 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artivion has higher revenue and earnings than Pulse Biosciences. Artivion is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.50	$9.77M	-$0.07	N/A
Pulse Biosciences	$350K	10,215.43	-$72.78M	-$1.18	N/A

Artivion has a net margin of -0.67% compared to Pulse Biosciences' net margin of -6,755.78%. Artivion's return on equity of 6.07% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Summary

Artivion beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Artivion (NYSE:AORT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

iRhythm Technologies currently has a consensus price target of $180.07, indicating a potential upside of 65.07%. Artivion has a consensus price target of $44.83, indicating a potential upside of 98.32%. Given Artivion's higher possible upside, analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

86.4% of Artivion shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

iRhythm Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Artivion has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

In the previous week, iRhythm Technologies had 9 more articles in the media than Artivion. MarketBeat recorded 10 mentions for iRhythm Technologies and 1 mentions for Artivion. iRhythm Technologies' average media sentiment score of 0.20 beat Artivion's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artivion has a net margin of -0.67% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Artivion	-0.67%	6.07%	2.93%

Artivion has lower revenue, but higher earnings than iRhythm Technologies. Artivion is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$825.34M	4.36	-$44.55M	-$0.43	N/A
Artivion	$441.33M	2.50	$9.77M	-$0.07	N/A

Summary

iRhythm Technologies beats Artivion on 10 of the 17 factors compared between the two stocks.

How does Artivion compare to AtriCure?

Artivion (NYSE:AORT) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

AtriCure has a net margin of 1.85% compared to Artivion's net margin of -0.67%. Artivion's return on equity of 6.07% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
AtriCure	1.85%	2.34%	1.77%

Artivion has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

86.4% of Artivion shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, AtriCure had 4 more articles in the media than Artivion. MarketBeat recorded 5 mentions for AtriCure and 1 mentions for Artivion. AtriCure's average media sentiment score of 0.22 beat Artivion's score of 0.00 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artivion presently has a consensus target price of $44.83, indicating a potential upside of 98.32%. AtriCure has a consensus target price of $53.30, indicating a potential downside of 5.45%. Given Artivion's stronger consensus rating and higher probable upside, equities analysts clearly believe Artivion is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Artivion has higher earnings, but lower revenue than AtriCure. Artivion is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.50	$9.77M	-$0.07	N/A
AtriCure	$534.53M	5.36	-$11.45M	$0.21	268.43

Summary

AtriCure beats Artivion on 10 of the 16 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.09B	$5.44B	$7.15B	$22.80B
Dividend Yield	N/A	1.81%	2.54%	3.73%
P/E Ratio	-322.91	25.76	274.34	27.91
Price / Sales	2.50	69.26	599.96	22.92
Price / Cash	20.25	32.73	27.22	19.11
Price / Book	2.39	6.04	11.07	4.70
Net Income	$9.77M	$146.97M	$3.49B	$1.07B
7 Day Performance	-1.21%	-0.38%	-1.37%	0.44%
1 Month Performance	-11.66%	-4.21%	-6.03%	-5.38%
1 Year Performance	-44.58%	2.13%	7.25%	5.38%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	2.8745 of 5 stars	$22.61 +1.3%	$44.83 +98.3%	-45.0%	$1.09B	$441.33M	N/A	1,800
ITGR Integer	2.29 of 5 stars	$126.35 +0.0%	$109.86 -13.1%	+20.3%	$4.30B	$1.85B	34.52	11,000	High Trading Volume
LIVN LivaNova	2.6125 of 5 stars	$77.21 +0.8%	$84.13 +9.0%	+43.2%	$4.22B	$1.39B	22.84	3,300
PLSE Pulse Biosciences	1.9424 of 5 stars	$52.32 +1.3%	$50.20 -4.1%	+161.8%	$3.66B	$350K	N/A	116
IRTC iRhythm Technologies	3.4971 of 5 stars	$112.60 +2.0%	$179.93 +59.8%	-37.9%	$3.64B	$747.14M	N/A	2,400	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors